StreetInsider.com News Articles

Form S-8 JUPITER NEUROSCIENCES,

Tue, 13 Oct 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20261013/27176184.html

Jupiter Neurosciences doses first patient in Parkinson's Phase 2a trial

Tue, 06 Oct 2026 11:15:13 -0400

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) announced that the first patient has been dosed in its Phase 2a RESET clinical trial evaluating JOTROL™ in patients with Parkinson's disease.

The RESET study (NCT07592767) is a multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics and biomarker effects of JOTROL™, the company's micellar formulation of trans-resveratrol. Georgetown University is the study sponsor, with Fernando L. Pagan, MD, professor of neurology at Georgetown University School of Medicine, serving as principal investigator.

The trial is expected to enroll approximately 30 patients who will be randomized to receive one of two dose levels of JOTROL™

Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value

Tue, 06 Oct 2026 11:15:00 -0400

First Patient Dosed with JOTROL^™ Marks Major Clinical Milestone for Jupiter Neurosciences’
Phase 2a Study Evaluating Safety, Pharmacokinetics and Biomarkers of JOTROL^™ in Patients with Parkinson’s Disease

Tungsten Advisors has been retained to identify strategic options to monetize Jupiter’s existing clinical development programs via corporate partners and explore other strategic options for a transaction to maximize shareholder value

Jupiter, FL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage biopharmaceutical company developing investigational therapies for neurodegenerative diseases, today announced that the first patient has been dosed in the company’s

Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson’s Disease and Exploration of Strategic Options to Maximize Shareholder Value

Tue, 06 Oct 2026 11:15:00 -0400

Form S-3 JUPITER NEUROSCIENCES,

Fri, 25 Sep 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260925/27103750.html

Form SCHEDULE 13G JUPITER NEUROSCIENCES, Filed by: PharmAla Biotech Holdings Inc.

Tue, 22 Sep 2026 11:59:00 -0400

si-local-file:///var/storage/secattach/20260922/27089855.html

Form SCHEDULE 13G/A JUPITER NEUROSCIENCES, Filed by: Orca Capital AG

Fri, 28 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26998917.html

Form SCHEDULE 13G/A JUPITER NEUROSCIENCES, Filed by: Orca Capital AG

Fri, 28 Aug 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26998917.html

Form SCHEDULE 13G JUPITER NEUROSCIENCES, Filed by: Orca Capital AG

Fri, 28 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260828/26998875.html

Form SCHEDULE 13G JUPITER NEUROSCIENCES, Filed by: Orca Capital AG

Fri, 28 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260828/26998875.html

Form 8-K JUPITER NEUROSCIENCES, For: Aug 27

Fri, 28 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260828/26997845.html

Form 8-K JUPITER NEUROSCIENCES, For: Aug 27

Fri, 28 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260828/26997845.html

Form 8-K JUPITER NEUROSCIENCES, For: Aug 26

Thu, 27 Aug 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260827/26984317.html

Form 8-K JUPITER NEUROSCIENCES, For: Aug 26

Thu, 27 Aug 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260827/26984317.html

Form 8-K JUPITER NEUROSCIENCES, For: Aug 24

Mon, 24 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260824/26968894.html

Form 8-K JUPITER NEUROSCIENCES, For: Aug 24

Mon, 24 Aug 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260824/26968894.html

Form 8-K JUPITER NEUROSCIENCES, For: Aug 21

Mon, 24 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260824/26964497.html

Form 8-K JUPITER NEUROSCIENCES, For: Aug 21

Mon, 24 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260824/26964497.html

Form 424B5 JUPITER NEUROSCIENCES,

Mon, 24 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26964439.html

Form 424B5 JUPITER NEUROSCIENCES,

Mon, 24 Aug 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260824/26964439.html

Jupiter Neurosciences prices $2M registered direct offering of shares

Fri, 21 Aug 2026 12:20:08 -0400

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) announced it has entered into a securities purchase agreement for a registered direct offering of 307,692 shares of common stock, with gross proceeds of approximately $2.0 million, according to a company press release.

D. Boral Capital LLC is acting as the exclusive placement agent for the offering. The closing is expected to occur on or about August 24, 2026, subject to customary closing conditions.

The shares are being offered pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declared effective by the U.S. Securities and Exchange Commission on April 24, 2026.

Jupiter

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Fri, 21 Aug 2026 12:20:00 -0400

New York, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced it has entered into a securities purchase agreement for the purchase and sale of 307,692 shares of common stock in a registered direct offering.

The gross proceeds of the offering are approximately $2.0 million (the "Offering").

D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.

The closing of the Offering is expected to occur on

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Fri, 21 Aug 2026 12:20:00 -0400

The gross proceeds of the offering are approximately $2.0 million (the "Offering").

D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.

The closing of the Offering is expected to occur on

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Fri, 21 Aug 2026 12:20:00 -0400

The gross proceeds of the offering are approximately $2.0 million (the "Offering").

D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.

The closing of the Offering is expected to occur on

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering

Fri, 21 Aug 2026 12:20:00 -0400

The gross proceeds of the offering are approximately $2.0 million (the "Offering").

D. Boral Capital LLC is acting as the exclusive placement agent for the Offering.

The closing of the Offering is expected to occur on